W. Niryana, Ida Bagus, Adiguna Wibawa, Gede Febby, Pratama Kusuma
{"title":"Recent Updates of Stem Cell Therapy in Spontaneous Intracerebral Haemorrhage Patients: A Review Article","authors":"W. Niryana, Ida Bagus, Adiguna Wibawa, Gede Febby, Pratama Kusuma","doi":"10.14710/dmj.v13i4.44046","DOIUrl":null,"url":null,"abstract":"Background: Spontaneous intracerebral haemorrhage (sICH) is a severe neurological condition with high disability and mortality rates globally. Effective therapeutic strategies to overcome the acute and long-term problems caused by sICH are still lacking. Mesenchymal stem cell (MSCs) therapy with the neuroprotective and neuroregenerative properties has the potential to overcome the complex brain injury mechanisms caused by sICH.Objective: This review highlights the recent pre-clinical and clinical findings about MSCs therapy in sICH case and their mechanisms in promoting neurological recovery.Methods: This is a literature review study. Study reports available from various accredited database such as PubMed and Google Scholar are collected using the following keywords: ((“stroke” or “intracerebral haemorrhage”)) and (“stem cell”).Results: Pre-clinical studies proved that MSCs therapy can resolved the secondary brain insult caused by sICH and improved the brain functional and clinical status. The clinical studies proved that MSCs therapy are safe and well tolerated in human bodies. There were also beneficial MSCs therapy effects in sICH patients. However, the clinical studies results were still lacking and some were inconclusive.Conclusion: The preclinical studies of stem cell therapy in spontaneous intracerebral haemorrhage showed promising evidences and the potential of stem cell therapy for clinical use. However, the clinical studies were still lacking. Further clinical studies are needed to confirm the neuroprotective and neuroregenerative benefits of MSCs therapy from the pre-clinical studies.","PeriodicalId":426927,"journal":{"name":"Jurnal Kedokteran Diponegoro (Diponegoro Medical Journal)","volume":"79 3","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Jurnal Kedokteran Diponegoro (Diponegoro Medical Journal)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14710/dmj.v13i4.44046","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Spontaneous intracerebral haemorrhage (sICH) is a severe neurological condition with high disability and mortality rates globally. Effective therapeutic strategies to overcome the acute and long-term problems caused by sICH are still lacking. Mesenchymal stem cell (MSCs) therapy with the neuroprotective and neuroregenerative properties has the potential to overcome the complex brain injury mechanisms caused by sICH.Objective: This review highlights the recent pre-clinical and clinical findings about MSCs therapy in sICH case and their mechanisms in promoting neurological recovery.Methods: This is a literature review study. Study reports available from various accredited database such as PubMed and Google Scholar are collected using the following keywords: ((“stroke” or “intracerebral haemorrhage”)) and (“stem cell”).Results: Pre-clinical studies proved that MSCs therapy can resolved the secondary brain insult caused by sICH and improved the brain functional and clinical status. The clinical studies proved that MSCs therapy are safe and well tolerated in human bodies. There were also beneficial MSCs therapy effects in sICH patients. However, the clinical studies results were still lacking and some were inconclusive.Conclusion: The preclinical studies of stem cell therapy in spontaneous intracerebral haemorrhage showed promising evidences and the potential of stem cell therapy for clinical use. However, the clinical studies were still lacking. Further clinical studies are needed to confirm the neuroprotective and neuroregenerative benefits of MSCs therapy from the pre-clinical studies.
背景:自发性脑出血(sICH)是一种严重的神经系统疾病,全球致残率和死亡率都很高。目前仍缺乏有效的治疗策略来解决自发性脑内出血引起的急性和长期问题。具有神经保护和神经再生特性的间充质干细胞(MSCs)疗法有望克服sICH引起的复杂脑损伤机制:本综述重点介绍了间充质干细胞治疗sICH病例的最新临床前和临床研究结果及其促进神经功能恢复的机制:这是一项文献综述研究。方法:这是一项文献综述研究,使用以下关键词从 PubMed 和 Google Scholar 等多个认证数据库中收集研究报告:("中风 "或 "脑出血")和("干细胞"):结果:临床前研究证明,间充质干细胞治疗可缓解脑出血引起的继发性脑损伤,改善脑功能和临床状态。临床研究证明,间充质干细胞疗法对人体安全且耐受性良好。同时,间充质干细胞疗法对 sICH 患者也有益处。然而,临床研究结果仍然不足,有些还没有定论:干细胞疗法治疗自发性脑出血的临床前研究显示,干细胞疗法具有良好的临床应用前景和潜力。然而,临床研究仍然缺乏。要证实临床前研究中间叶干细胞疗法对神经保护和神经再生的益处,还需要进一步的临床研究。